Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 26 for:    crispr

Safety of Transplantation of CRISPR CCR5 Modified CD34+ Cells in HIV-infected Subjects With Hematological Malignances

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03164135
Recruitment Status : Recruiting
First Posted : May 23, 2017
Last Update Posted : May 23, 2017
Sponsor:
Collaborators:
Peking University
Capital Medical University
Information provided by (Responsible Party):
Chen Hu, Affiliated Hospital to Academy of Military Medical Sciences

Tracking Information
First Submitted Date  ICMJE May 18, 2017
First Posted Date  ICMJE May 23, 2017
Last Update Posted Date May 23, 2017
Estimated Study Start Date  ICMJE May 30, 2017
Estimated Primary Completion Date May 20, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 22, 2017)
Persistence of CCR5 gene disruption in engrafted cells [ Time Frame: 12 months ]
Participants will be transplanted with CD34+ cells which are treated using the CRISPR/Cas9 system to disrupt CCR5 gene. The persistence of CCR5 gene disruption in engrafted cells will be evaluated by sequencing.
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: May 22, 2017)
CD34+ cell number [ Time Frame: the first month ]
The CD34+ cell number pre-infusion
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: May 22, 2017)
  • Gene disruption efficiency of bone marrow cells [ Time Frame: Up to Month 12 ]
    The percentage of disrupted CCR5 gene alleles in genome from bone marrow cells detected by sequencing.
  • CCR5 gene disruption efficiency of peripheral blood cells [ Time Frame: Up to Month 12 ]
    The percentage of disrupted CCR5 gene alleles in genome of peripheral blood cells by sequencing.
  • Hematopoietic cell engraftment [ Time Frame: Up to Year 3 ]
    Measurement of multi-lineage hematopoietic cell engraftment time after transplantation to evaluate the hematological recovery
  • HIV-1 RNA level [ Time Frame: Up to Year 3 ]
    Level change of HIV-1 RNA in plasma after transplantation
  • CD4+ T cell number [ Time Frame: Up to Year 3 ]
    Level change of the CD4+ T cell number after transplantation
  • The ratio change of CD4/CD8 [ Time Frame: Up to Year 3 ]
    The ratio change of CD4/CD8 in peripheral blood after transplantation
  • HIV-1 RNA levels during ATI [ Time Frame: Every two weeks, until the end of ATI or up to 3 months ]
    HIV-1 RNA levels in plasma during ATI.
  • HIV-1 DNA level [ Time Frame: Up to Month 12 ]
    Changes of proviral DNA in PBMC pre- transplantation and 12 month post-transplantation
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Safety of Transplantation of CRISPR CCR5 Modified CD34+ Cells in HIV-infected Subjects With Hematological Malignances
Official Title  ICMJE Safety and Feasibility Study of Allotransplantation of CRISPR/Cas9 CCR5 Gene Modified CD34+ Hematopoietic Stem/Progenitor Cells in HIV-infected Subjects With Hematological Malignances
Brief Summary The investigators performed this study to evaluate the safety and feasibility of transplantation with CRISPR/Cas9 CCR5 gene modified CD34+ hematopoietic stem/progenitor cells for patients that develop AIDS and hematological malignances. Patients will be treated with antiviral therapy (ART) to achieve undetectable HIV-1 virus in peripheral blood before conditioning. CD34+ cells from donors will be infused into the patients after treatment with CRISPR/Cas9 to ablate CCR5 gene.
Detailed Description The primary objective of this study is to determine the safety of the infusion of CD34+ cells which are treated with CRISPR/Cas9 to disrupt the CCR5 gene. The secondary objective is to evaluate the resistance to HIV-1(R5) in infected patients after infusion of modified CD34+ cells with or without an antiretroviral therapy interruption (ATI). After the transplantation, the reconstitution time and frequency of multi-lineage hematopoietic cell will be analyzed against previously reported HSCT in HIV-1 patients. After the detection of high CD4+ T cells reconstitution (over 600 cells/μL) and CCR5 negative cells (over 1%) in peripheral blood, subjects will undergo an ATI. HIV-1 RNA level and CD4+ cell counts will be monitored biweekly for at least one month.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Intervention Model: Single Group Assignment
Intervention Model Description:
CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 before transplantation into the patient.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE HIV-1-infection
Intervention  ICMJE Genetic: CCR5 gene modification
CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 targeting CCR5 gene.
Study Arms  ICMJE Experimental: CCR5 gene modification
CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 before transplantation into the patient.
Intervention: Genetic: CCR5 gene modification
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 22, 2017)
5
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 20, 2021
Estimated Primary Completion Date May 20, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Age between 18 to 60, male of female;
  2. Hematological neoplasms;
  3. HIV-1 R5 tropic virus with no CXCR4-tropic or R5/X4 dual-tropic HIV;
  4. On ART with undetectable HIV-1 level (<40gc/ml, HIV-1 RNA);
  5. Availability of a consenting HLA-matched donor;
  6. No cardiomyopathy or congestive heart failure;
  7. CD4+ T-cell counts ≥200 cells/µL and ≤750 cells/µL;
  8. Absence of psychosocial conditions and be willing to comply with study-mandated evaluations for 2 years;
  9. Life expectancy of at least 1 year.

Exclusion Criteria:

  1. Acute or chronic hepatitis B or hepatitis C infection;
  2. Any cancer or malignancy other than hematological neoplasms;
  3. Subject with CMV retinitis or other active CMV infection related diseases;
  4. Subject with organ dysfunction;
  5. Non-pregnant and non-nursing;
  6. Drug or alcohol abuse or dependence;
  7. Currently enrolled in another clinical trial or underwent cell therapy;
  8. Donor incapable for HSPC mobilization;
  9. in the opinion of the site investigator, would interfere with adherence to study requirements.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Bin Zhang, MD, PhD +86-10-66947625 zb307ctc@163.com
Contact: Hu Chen, MD, PhD +86-10-66947108 chenhu217@aliyun.com
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03164135
Other Study ID Numbers  ICMJE 307-HSPC-R5
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Chen Hu, Affiliated Hospital to Academy of Military Medical Sciences
Study Sponsor  ICMJE Affiliated Hospital to Academy of Military Medical Sciences
Collaborators  ICMJE
  • Peking University
  • Capital Medical University
Investigators  ICMJE Not Provided
PRS Account Affiliated Hospital to Academy of Military Medical Sciences
Verification Date May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP